← Russell 3000 cross-section

ALLO Allogene Therapeutics, Inc.

Trailing twelve months to 2025-12-31 · as filed 2026-03-12, not restated
Healthcare

Scale

Market cap
$708m
Revenue TTM
$0m
Net income TTM
$-191m
Free cash flow
$-150m
Composite score
29.8
Sector rank
#2222

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-21.14%
Earnings yield vs 10-yr
-31.70pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-65.2%
ROIC
-494.5%
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$-0.06m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

If Notch subsequently out-licenses any of the Released Targets (whether through an out-license, partnership, sale, or other transaction), we will be entitled to receive a percentage of upfront and/or milestone payments associated therewith up to a set cap of $30.0 million, and will be entitled to a low, single-digit royalty on net sales of products containing a Released Target. Under the License Amendment, we continued to grant Allogene Overland PRC an exclusive license to develop, manufacture, and commercialize the Overland Licensed Products in the JV Territory, with us retaining exclusive rights to the Overland Licensed Products outside the JV Territory, and the royalty obligations to us w …Allogene Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →